Severe Esophagitis and Gastritis from Nivolumab Therapy

Overview

Journal ACG Case Rep J

Specialty Gastroenterology

Date 2017 May 2

PMID 28459081

Citations 30

Authors

Justin Boike

Todd Dejulio

Affiliations

Soon will be listed here.

Abstract

Nivolumab is a novel chemotherapy currently approved for the treatment of multiple metastatic malignancies. This class of therapy, known as immune checkpoint inhibitors, is notable for an autoimmune-related adverse event profile. Diarrhea and colitis are common gastrointestinal adverse events, however, upper gastrointestinal events are rarely reported. We present a case of nivolumab-associated esophagitis and gastritis that has yet to be reported in the published literature.

Citing Articles

Upper gastrointestinal tract immune-related adverse events: Two cases of obstructive complications occurred in immune consolidation therapy after sequential chimeric antigen receptor T cell therapy with autologous hematopoietic stem cell....

Zhang Q, Li C, Cao Y, Wang N, Huang L, Shang Z Clin Case Rep. 2024; 12(1):e8411.

PMID: 38235413 PMC: 10792699. DOI: 10.1002/ccr3.8411.

Nivolumab-induced tumour-like gastritis: A case report.

Cijauskaite E, Kazenaite E, Strainiene S, Sadauskaite G, Kurlinkus B World J Clin Cases. 2023; 11(18):4350-4359.

PMID: 37449232 PMC: 10336988. DOI: 10.12998/wjcc.v11.i18.4350.

Immune Checkpoint Inhibitor-Induced Lymphocytic Esophagitis.

Amin S, Munankami S, Desai P, Altomare J, Shah N Cureus. 2023; 15(6):e39920.

PMID: 37409215 PMC: 10317789. DOI: 10.7759/cureus.39920.

Adverse Effects of Immune-Checkpoint Inhibitors: A Comprehensive Imaging-Oriented Review.

Mallio C, Bernetti C, Cea L, Buoso A, Stiffi M, Vertulli D Curr Oncol. 2023; 30(5):4700-4723.

PMID: 37232813 PMC: 10217557. DOI: 10.3390/curroncol30050355.

Multiple White Plaques in the Esophagus: A Possible Case of Esophageal Mucosal Alteration Associated With Immune-Related Adverse Events of Immune Checkpoint Inhibitors.

Iwamuro M, Tanaka T, Kono Y, Kawano S, Okada H Cureus. 2023; 14(12):e32710.

PMID: 36686096 PMC: 9848826. DOI: 10.7759/cureus.32710.

References

Borghaei H, Paz-Ares L, Horn L, Spigel D, Steins M, Ready N . Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(17):1627-39. PMC: 5705936. DOI: 10.1056/NEJMoa1507643. View

Topalian S, Taube J, Anders R, Pardoll D . Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016; 16(5):275-87. PMC: 5381938. DOI: 10.1038/nrc.2016.36. View

Eigentler T, Hassel J, Berking C, Aberle J, Bachmann O, Grunwald V . Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treat Rev. 2016; 45:7-18. DOI: 10.1016/j.ctrv.2016.02.003. View

Berman D, Parker S, Siegel J, Chasalow S, Weber J, Galbraith S . Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun. 2010; 10:11. PMC: 2999944. View

Villadolid J, Amin A . Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl Lung Cancer Res. 2015; 4(5):560-75. PMC: 4630514. DOI: 10.3978/j.issn.2218-6751.2015.06.06. View

Ansell S, Lesokhin A, Borrello I, Halwani A, Scott E, Gutierrez M . PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2014; 372(4):311-9. PMC: 4348009. DOI: 10.1056/NEJMoa1411087. View

Motzer R, Escudier B, Mcdermott D, George S, Hammers H, Srinivas S . Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015; 373(19):1803-13. PMC: 5719487. DOI: 10.1056/NEJMoa1510665. View

Merrill S, Reynolds P, Kalra A, Biehl J, Vandivier R, Mueller S . Early administration of infliximab for severe ipilimumab-related diarrhea in a critically ill patient. Ann Pharmacother. 2014; 48(6):806-10. DOI: 10.1177/1060028014528152. View

Robert C, Long G, Brady B, Dutriaux C, Maio M, Mortier L . Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2014; 372(4):320-30. DOI: 10.1056/NEJMoa1412082. View

10.

Keir M, Butte M, Freeman G, Sharpe A . PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008; 26:677-704. PMC: 10637733. DOI: 10.1146/annurev.immunol.26.021607.090331. View

11.

Ferris R, Blumenschein Jr G, Fayette J, Guigay J, Colevas A, Licitra L . Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016; 375(19):1856-1867. PMC: 5564292. DOI: 10.1056/NEJMoa1602252. View

12.

Spain L, Diem S, Larkin J . Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016; 44:51-60. DOI: 10.1016/j.ctrv.2016.02.001. View

13.

Weber J, Thompson J, Hamid O, Minor D, Amin A, Ron I . A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res. 2009; 15(17):5591-8. DOI: 10.1158/1078-0432.CCR-09-1024. View